Skip to Content

Genomics

a research organization

Discover more

Founder Genomics is a research organization dedicated to advancing antibiotic therapies, with a particular focus on tuberculosis (TB). Their multidisciplinary team, comprising experts in theoretical biology, biochemistry, physics, statistics, and engineering, employs mathematical models, experimental data, and clinical insights to optimize drug treatment strategies at both individual and population levels.

Antibiotics : 

Investigating the mechanisms of antibiotic efficacy and resistance, especially concerning multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains. The goal is to develop strategies that enhance the effectiveness of existing antibiotics and support the discovery of new drug candidates.

Population Biology : 

Exploring how bacterial populations evolve under selective pressures, such as drug treatments and host immune responses. This research aims to inform strategies to slow the spread of resistance and optimize public health outcomes.ons de conception durables

Biochemistry and Pharmacology : 

Studying the biochemical interactions between drugs and their bacterial targets, including drug absorption, distribution, metabolism, and elimination (ADME) processes. These insights help identify promising compounds, optimize dosing strategies, and reduce off-target effects.

 

Our Approach

1

Innovative Research & Development

We leverage state-of-the-art technologies, including genomics, proteomics, and artificial intelligence, to identify novel drug targets and optimize antibiotic candidates. 

2

Collaboration Across Disciplines 

TBInnovate partners with leading academic institutions, biotech firms, and global health organizations to accelerate breakthroughs in TB treatment.


 

4

Tackling Resistance Head-On 

Our work focuses on creating drugs that remain effective against MDR-TB and XDR-TB strains, ensuring lasting efficacy in the face of evolving bacterial resistance.

3

Patient-Centric Solutions 

We prioritize therapies that are:

  • Shorter in duration
  • More tolerable for patients
  • Affordable and accessible in resource-limited settings

Adeno-Associated Virus (AAV): A Powerful Tool for Gene Therapy and Genetic Manipulation

Adeno-associated virus (AAV), a member of the Parvoviridae family, is a single-stranded DNA vi rus widely used in gene therapy, gene expression, and gene manipulation. With its replication-defective nature, rAAV (recombinant AAV) has become an indispensable tool in genetic research and therapeutic applications.


Structure and Genome of AAV

The AAV genome is a single-stranded DNA molecule that is approximately 4.7 kb in length. It consists of two main genes:

  • Rep gene : Responsible for viral replication.
  • Cap gene : Encodes the capsid protein necessary for packaging the viral genome.

These genes are flanked by inverted terminal repeat (ITR) sequences, which are crucial for the vir us's replication and packaging processes. The AAV particle, with a diameter of approximately 20 nm, is icosahedral in shape and lacks an envelope, making it a robust vector for gene delivery.


rAAV : The Modified Vir us with Increased Potential

In recombinant AAV (rAAV), the AAV genome conserves only the ITRs, while the viral DNA between them is replaced with the gene of interest. This modification allows for the delivery of foreign genes without the risks associated with full viral replication. The ITRs serve as cis-elements that are essential for viral genome replication and packaging, while the Rep, Cap, and helper genes are provided trans (separately) for viral packaging.

Why Choose AAV for Your Research or Therapy ?

  • Exceptional Safety Profile : With low immunogenicity and the ability to transduce a wide variety of host cells, AAV is an ideal choice for both clinical gene therapy and basic research.
  • Stability and Longevity : rAAV provides stable, long-term gene expression without the need for continuous viral replication.
  • Versatility : The availability of multiple serotypes enables researchers to target specific tissues and cell types effectively.

Discover more

#

AAV Vector

LV Vector

Retroviral Vector

Adenovirus Vector

Diamete

20-30 nm

90-110 nm

90-100 nm

60-90 nm

Copy type

/

/

/

active

Gene capacity

2.5 kb

4 kb

1.6 kb

5-6 kb

Integration mechanism

Directional low frequency

random high frequency

random high frequency

non-integrated

Cell infection

serotype determination

Wide range

split cell

Wide range

Titer range

vg/ml

tu/ml

tu/ml

/ml

In vitro infection

available

recommended

available

available

Immunogenicity

weak

normal

normal

weak

Positioning injection

recommended

available

recommended

available

Diffusion ability

strong

normal

normal

strong

Start time

2-3 weeks

3-4 days

3-4 days

2-3 days

Duration

>3 months

>2 months

> 2 months

< 10 days